Therapeutic Solutions International, Inc. engages in the provision of immune modulation for the treatment of several specific diseases. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. The company has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. The company has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.
Follow-Up Questions
Therapeutic Solutions International Inc のCEOは誰ですか?
Mr. Timothy Dixon は Therapeutic Solutions International Inc の Chairman of the Board で、2011 から在籍しています。
TSOI の株価パフォーマンスは?
TSOI の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Therapeutic Solutions International Inc の主な事業テーマや業界は?
Therapeutic Solutions International Inc は N/A 業界、セクターは N/A に属しています。
Therapeutic Solutions International Inc の時価総額はいくらですか?
Therapeutic Solutions International Inc の現在の時価総額は $5.1K です。